- Generic drugmaker, Endo International ( NASDAQ: ENDP ) disclosed that the company is not currently in compliance with the $1.00 minimum bid price requirement for listing on the Nasdaq.
- According to a notice received from Nasdaq on July 01, Endo ( ENDP ) said it had 180 days, or until December 28, 2022, to regain compliance when its shares meet or exceed $1.00 threshold for a minimum of 10 consecutive business days.
- If the company cannot meet that requirement by December, it may be eligible for an additional 180-day grace period, Endo ( ENDP ) said.
- However, the company added that there can be no assurance it can meet the minimum bid price requirement during the 180-day compliance period or secure the 180-day grace period.
- “The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the minimum bid requirement,” Endo ( ENDP ) added.
- Endo ( ENDP ) has added ~27% in the pre-market on Tuesday so far.
- Read: Endo ( ENDP ) shares spiked on Friday after favorable verdict in an antitrust trial related to its pain therapy Opana ER.
For further details see:
Endo at risk of delisting from Nasdaq